INT148899

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 2008
Last Reported 2009
Negated 1
Speculated 1
Reported most in Abstract
Documents 2
Total Number 5
Disease Relevance 2.72
Pain Relevance 3.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Sort1) endosome (Sort1) transport (Sort1)
Golgi apparatus (Sort1) endoplasmic reticulum (Sort1) intracellular (Sort1)
Sort1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
intrathecal 30 100.00 Very High Very High Very High
agonist 144 99.98 Very High Very High Very High
Spinal cord 56 99.08 Very High Very High Very High
antinociception 26 99.02 Very High Very High Very High
Dorsal horn 34 98.32 Very High Very High Very High
Pain management 3 98.08 Very High Very High Very High
Inflammation 42 97.80 Very High Very High Very High
dorsal root ganglion 13 95.72 Very High Very High Very High
Pain 153 94.52 High High
Eae 15 85.84 High High
Disease Link Frequency Relevance Heat
Pain 192 98.40 Very High Very High Very High
Nociception 138 98.20 Very High Very High Very High
INFLAMMATION 45 97.80 Very High Very High Very High
Injury 12 95.92 Very High Very High Very High
Ganglion Cysts 16 95.72 Very High Very High Very High
Inflammatory Pain 12 85.84 High High
Low Back Pain 7 82.12 Quite High
Disease 4 51.48 Quite High
Toxicity 3 47.60 Quite Low
Urological Neuroanatomy 9 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Unlike NTS2 drugs, the NT69L agonist, acting on both NTS1 and NTS2 receptors, was able to reverse all nociceptive endpoint behaviors observed following tissue injury by intraplantar formalin (Fig. 4).
Regulation (acting) of NTS1 associated with nociception, injury and agonist
1) Confidence 0.50 Published 2009 Journal Mol Pain Section Body Doc Link PMC2714839 Disease Relevance 0.69 Pain Relevance 0.56
We then examined the effects of intrathecal injection of NT (1-15 microg/kg) or NTS1 preferring agonists on the nocifensive response to intraplantar formalin.
Spec (examined) Regulation (effects) of NTS1 associated with agonist and intrathecal
2) Confidence 0.26 Published 2008 Journal J. Neurochem. Section Abstract Doc Link 18182046 Disease Relevance 0.55 Pain Relevance 1.18
Therefore, JMV-431 and levocabastine were used in the behavioral experiments as selective ligands for NTS2, whereas NT69L and NT were considered as agonists acting on both NTS1 and NTS2 in a non-discriminative manner.


Regulation (acting) of NTS1 associated with agonist
3) Confidence 0.22 Published 2009 Journal Mol Pain Section Body Doc Link PMC2714839 Disease Relevance 0.24 Pain Relevance 0.24
In conclusion, development of NT agonists targeting both NTS1 and NTS2 receptors could be useful for chronic pain management.



Regulation (targeting) of NTS1 associated with pain, pain management and agonist
4) Confidence 0.22 Published 2009 Journal Mol Pain Section Abstract Doc Link PMC2714839 Disease Relevance 0.84 Pain Relevance 0.91
In order to ensure that these findings were not biased by unsuspected off-target effects (OTEs), we also demonstrated that treatment with a second NTS2-specific DsiRNA also reversed NTS2-induced antinociception, and that NTS2-specific 27-mer duplexes did not alter signaling through NTS1, a closely related receptor.
Neg (not) Regulation (alter) of NTS1 associated with antinociception
5) Confidence 0.01 Published 2008 Journal Mol. Ther. Section Abstract Doc Link 18523447 Disease Relevance 0.39 Pain Relevance 0.57

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox